1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Echinochrome	_	_	NNP	_	_	_	_	_
2	A	_	_	NNP	_	_	_	_	_
3	(	_	_	-LRB-	_	_	_	_	_
4	Ech	_	_	NNP	_	_	_	_	_
5	A	_	_	NNP	_	_	_	_	_
6	)	_	_	-RRB-	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	dark	_	_	JJ	_	_	_	_	_
10	red	_	_	JJ	_	_	_	_	_
11	pigment	_	_	NN	_	_	_	_	_
12	separated	_	_	VBN	_	_	_	_	_
13	from	_	_	IN	_	_	_	_	_
14	sea	_	_	NN	_	_	_	_	_
15	urchin	_	_	NN	_	_	_	_	_
16	shell	_	_	NN	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	spine	_	_	NN	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	has	_	_	VBZ	_	_	_	_	_
21	a	_	_	DT	_	_	_	_	_
22	chemical	_	_	JJ	_	_	_	_	_
23	structure	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	6-ethyl-2,3,5,7,8-pentahydroxy-1,4-naphthoquinone	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	As	_	_	IN	_	_	_	_	_
2	a	_	_	DT	_	_	_	_	_
3	main	_	_	JJ	_	_	_	_	_
4	active	_	_	JJ	_	_	_	_	_
5	component	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	commercial	_	_	JJ	_	_	_	_	_
9	therapeutic	_	_	JJ	_	_	_	_	_
10	agent	_	_	NN	_	_	_	_	_
11	called	_	_	VBN	_	_	_	_	_
12	‘	_	_	``	_	_	_	_	_
13	histochrome	_	_	NN	_	_	_	_	_
14	’	_	_	''	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	Ech	_	_	NNP	_	_	_	_	_
17	A	_	_	NNP	_	_	_	_	_
18	has	_	_	VBZ	_	_	_	_	_
19	been	_	_	VBN	_	_	_	_	_
20	used	_	_	VBN	_	_	_	_	_
21	for	_	_	IN	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	treatment	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	cardiovascular	_	_	JJ	_	_	_	_	_
26	disorders	_	_	NNS	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	ophthalmopathic	_	_	JJ	_	_	_	_	_
29	complications	_	_	NNS	_	_	_	_	_
30	in	_	_	IN	_	_	_	_	_
31	Russia	_	_	NNP	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	Among	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	several	_	_	JJ	_	_	_	_	_
4	biological	_	_	JJ	_	_	_	_	_
5	benefits	_	_	NNS	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	Ech	_	_	NNP	_	_	_	_	_
8	A	_	_	NNP	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	anti-oxidant	_	_	JJ	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	anti-inflammatory	_	_	JJ	_	_	_	_	_
13	capacity	_	_	NN	_	_	_	_	_
14	is	_	_	VBZ	_	_	_	_	_
15	proposed	_	_	VBN	_	_	_	_	_
16	as	_	_	IN	_	_	_	_	_
17	a	_	_	DT	_	_	_	_	_
18	major	_	_	JJ	_	_	_	_	_
19	underlying	_	_	JJ	_	_	_	_	_
20	therapeutic	_	_	JJ	_	_	_	_	_
21	mechanism	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Indeed	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	Ech	_	_	NNP	_	_	_	_	_
4	A	_	_	NNP	_	_	_	_	_
5	has	_	_	VBZ	_	_	_	_	_
6	been	_	_	VBN	_	_	_	_	_
7	shown	_	_	VBN	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	attenuate	_	_	VB	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	oxidative	_	_	JJ	_	_	_	_	_
12	stress	_	_	NN	_	_	_	_	_
13	caused	_	_	VBN	_	_	_	_	_
14	by	_	_	IN	_	_	_	_	_
15	reactive	_	_	JJ	_	_	_	_	_
16	oxygen	_	_	NN	_	_	_	_	_
17	species	_	_	NNS	_	_	_	_	_
18	(	_	_	-LRB-	_	_	_	_	_
19	ROS	_	_	NNPS	_	_	_	_	_
20	)	_	_	-RRB-	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	cardiac	_	_	JJ	_	_	_	_	_
23	toxic	_	_	JJ	_	_	_	_	_
24	drugs	_	_	NNS	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	providing	_	_	VBG	_	_	_	_	_
27	mitochondrial	_	_	JJ	_	_	_	_	_
28	protection	_	_	NN	_	_	_	_	_
29	of	_	_	IN	_	_	_	_	_
30	cardiomyocyte	_	_	NN	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_
32	Park	_	_	NNP	_	_	_	_	_
33	et	_	_	FW	_	_	_	_	_
34	al.	_	_	FW	_	_	_	_	_
35	have	_	_	VBP	_	_	_	_	_
36	reported	_	_	VBN	_	_	_	_	_
37	similar	_	_	JJ	_	_	_	_	_
38	observations	_	_	NNS	_	_	_	_	_
39	showing	_	_	VBG	_	_	_	_	_
40	that	_	_	IN	_	_	_	_	_
41	Ech	_	_	NNP	_	_	_	_	_
42	A	_	_	NNP	_	_	_	_	_
43	reduced	_	_	VBN	_	_	_	_	_
44	both	_	_	CC	_	_	_	_	_
45	cellular	_	_	JJ	_	_	_	_	_
46	and	_	_	CC	_	_	_	_	_
47	mitochondrial	_	_	JJ	_	_	_	_	_
48	ROS	_	_	NN	_	_	_	_	_
49	levels	_	_	NNS	_	_	_	_	_
50	of	_	_	IN	_	_	_	_	_
51	patient-derived	_	_	JJ	_	_	_	_	_
52	cardiac	_	_	JJ	_	_	_	_	_
53	progenitors	_	_	NNS	_	_	_	_	_
54	during	_	_	IN	_	_	_	_	_
55	the	_	_	DT	_	_	_	_	_
56	oxidative	_	_	JJ	_	_	_	_	_
57	stress	_	_	NN	_	_	_	_	_
58	situation	_	_	NN	_	_	_	_	_
59	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	anti-oxidative	_	_	JJ	_	_	_	_	_
3	and	_	_	CC	_	_	_	_	_
4	anti-viral	_	_	JJ	_	_	_	_	_
5	activity	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	Ech	_	_	NNP	_	_	_	_	_
8	A	_	_	NNP	_	_	_	_	_
9	has	_	_	VBZ	_	_	_	_	_
10	also	_	_	RB	_	_	_	_	_
11	been	_	_	VBN	_	_	_	_	_
12	proved	_	_	VBN	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	vitro	_	_	FW	_	_	_	_	_
15	using	_	_	VBG	_	_	_	_	_
16	a	_	_	DT	_	_	_	_	_
17	tick-borne	_	_	JJ	_	_	_	_	_
18	encephalitis	_	_	NN	_	_	_	_	_
19	virus	_	_	NN	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	herpes	_	_	NN	_	_	_	_	_
22	simplex	_	_	NN	_	_	_	_	_
23	virus	_	_	NN	_	_	_	_	_
24	type	_	_	NN	_	_	_	_	_
25	1-infected	_	_	VBN	_	_	_	_	_
26	cell	_	_	NN	_	_	_	_	_
27	models	_	_	NNS	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	therapeutic	_	_	JJ	_	_	_	_	_
3	potential	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	Ech	_	_	NNP	_	_	_	_	_
6	A	_	_	NNP	_	_	_	_	_
7	was	_	_	VBD	_	_	_	_	_
8	also	_	_	RB	_	_	_	_	_
9	evaluated	_	_	VBN	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	an	_	_	DT	_	_	_	_	_
12	experimental	_	_	JJ	_	_	_	_	_
13	gastric	_	_	JJ	_	_	_	_	_
14	ulcer	_	_	NN	_	_	_	_	_
15	model	_	_	NN	_	_	_	_	_
16	where	_	_	WRB	_	_	_	_	_
17	Ech	_	_	NNP	_	_	_	_	_
18	A	_	_	NNP	_	_	_	_	_
19	provided	_	_	VBD	_	_	_	_	_
20	anti-ulcerogenic	_	_	JJ	_	_	_	_	_
21	effects	_	_	NNS	_	_	_	_	_
22	by	_	_	IN	_	_	_	_	_
23	increasing	_	_	VBG	_	_	_	_	_
24	endogenous	_	_	JJ	_	_	_	_	_
25	enzymatic	_	_	JJ	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	non-enzymatic	_	_	JJ	_	_	_	_	_
28	antioxidant	_	_	NN	_	_	_	_	_
29	levels	_	_	NNS	_	_	_	_	_
30	in	_	_	IN	_	_	_	_	_
31	vivo	_	_	NN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	another	_	_	DT	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	Ech	_	_	NNP	_	_	_	_	_
6	A	_	_	NNP	_	_	_	_	_
7	treatment	_	_	NN	_	_	_	_	_
8	could	_	_	MD	_	_	_	_	_
9	reduce	_	_	VB	_	_	_	_	_
10	ROS	_	_	NN	_	_	_	_	_
11	production	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	pro-inflammatory	_	_	JJ	_	_	_	_	_
14	tumor	_	_	NN	_	_	_	_	_
15	necrosis	_	_	NN	_	_	_	_	_
16	factor-α	_	_	NN	_	_	_	_	_
17	(	_	_	-LRB-	_	_	_	_	_
18	TNF-α	_	_	NN	_	_	_	_	_
19	)	_	_	-RRB-	_	_	_	_	_
20	secretion	_	_	NN	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	a	_	_	DT	_	_	_	_	_
23	rat	_	_	NN	_	_	_	_	_
24	model	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	acute	_	_	JJ	_	_	_	_	_
27	uveitis	_	_	NN	_	_	_	_	_
28	induced	_	_	VBN	_	_	_	_	_
29	by	_	_	IN	_	_	_	_	_
30	lipopolysaccharide	_	_	NN	_	_	_	_	_
31	injection	_	_	NN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	previous	_	_	JJ	_	_	_	_	_
3	findings	_	_	NNS	_	_	_	_	_
4	imply	_	_	VBP	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	Ech	_	_	NNP	_	_	_	_	_
7	A	_	_	NNP	_	_	_	_	_
8	could	_	_	MD	_	_	_	_	_
9	exert	_	_	VB	_	_	_	_	_
10	a	_	_	DT	_	_	_	_	_
11	wide	_	_	JJ	_	_	_	_	_
12	range	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	therapeutic	_	_	JJ	_	_	_	_	_
15	impacts	_	_	NNS	_	_	_	_	_
16	on	_	_	IN	_	_	_	_	_
17	other	_	_	JJ	_	_	_	_	_
18	oxidative	_	_	JJ	_	_	_	_	_
19	stress-related	_	_	JJ	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	inflammatory	_	_	JJ	_	_	_	_	_
22	pathologic	_	_	JJ	_	_	_	_	_
23	conditions	_	_	NNS	_	_	_	_	_
24	;	_	_	:	_	_	_	_	_
25	however	_	_	RB	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	the	_	_	DT	_	_	_	_	_
28	cell-type	_	_	NN	_	_	_	_	_
29	specific	_	_	JJ	_	_	_	_	_
30	regulation	_	_	NN	_	_	_	_	_
31	of	_	_	IN	_	_	_	_	_
32	Ech	_	_	NNP	_	_	_	_	_
33	A	_	_	NNP	_	_	_	_	_
34	on	_	_	IN	_	_	_	_	_
35	the	_	_	DT	_	_	_	_	_
36	immune	_	_	JJ	_	_	_	_	_
37	system	_	_	NN	_	_	_	_	_
38	,	_	_	,	_	_	_	_	_
39	which	_	_	WDT	_	_	_	_	_
40	consists	_	_	VBZ	_	_	_	_	_
41	of	_	_	IN	_	_	_	_	_
42	various	_	_	JJ	_	_	_	_	_
43	innate	_	_	JJ	_	_	_	_	_
44	and	_	_	CC	_	_	_	_	_
45	adaptive	_	_	JJ	_	_	_	_	_
46	immune	_	_	JJ	_	_	_	_	_
47	cells	_	_	NNS	_	_	_	_	_
48	,	_	_	,	_	_	_	_	_
49	has	_	_	VBZ	_	_	_	_	_
50	not	_	_	RB	_	_	_	_	_
51	been	_	_	VBN	_	_	_	_	_
52	elucidated	_	_	VBN	_	_	_	_	_
53	yet	_	_	RB	_	_	_	_	_
54	.	_	_	.	_	_	_	_	_


1	Inflammatory	_	_	JJ	_	_	_	_	_
2	bowel	_	_	NN	_	_	_	_	_
3	disease	_	_	NN	_	_	_	_	_
4	(	_	_	-LRB-	_	_	_	_	_
5	IBD	_	_	NNP	_	_	_	_	_
6	)	_	_	-RRB-	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	an	_	_	DT	_	_	_	_	_
9	intractable	_	_	JJ	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	chronic	_	_	JJ	_	_	_	_	_
12	inflammatory	_	_	JJ	_	_	_	_	_
13	disease	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	digestive	_	_	JJ	_	_	_	_	_
17	tract	_	_	NN	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	Crohn	_	_	NNP	_	_	_	_	_
20	's	_	_	POS	_	_	_	_	_
21	disease	_	_	NN	_	_	_	_	_
22	(	_	_	-LRB-	_	_	_	_	_
23	CD	_	_	NN	_	_	_	_	_
24	)	_	_	-RRB-	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	ulcerative	_	_	JJ	_	_	_	_	_
27	colitis	_	_	NN	_	_	_	_	_
28	(	_	_	-LRB-	_	_	_	_	_
29	UC	_	_	NNP	_	_	_	_	_
30	)	_	_	-RRB-	_	_	_	_	_
31	are	_	_	VBP	_	_	_	_	_
32	the	_	_	DT	_	_	_	_	_
33	major	_	_	JJ	_	_	_	_	_
34	types	_	_	NNS	_	_	_	_	_
35	of	_	_	IN	_	_	_	_	_
36	IBD	_	_	NN	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	etiology	_	_	NN	_	_	_	_	_
3	and	_	_	CC	_	_	_	_	_
4	pathogenic	_	_	JJ	_	_	_	_	_
5	mechanisms	_	_	NNS	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	IBD	_	_	NNP	_	_	_	_	_
8	remain	_	_	VBP	_	_	_	_	_
9	largely	_	_	RB	_	_	_	_	_
10	unknown	_	_	JJ	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	both	_	_	DT	_	_	_	_	_
13	environmental	_	_	JJ	_	_	_	_	_
14	factors	_	_	NNS	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	genetic	_	_	JJ	_	_	_	_	_
17	factors	_	_	NNS	_	_	_	_	_
18	combined	_	_	VBN	_	_	_	_	_
19	with	_	_	IN	_	_	_	_	_
20	immunological	_	_	JJ	_	_	_	_	_
21	dysfunction	_	_	NN	_	_	_	_	_
22	seem	_	_	VBP	_	_	_	_	_
23	to	_	_	TO	_	_	_	_	_
24	drive	_	_	VB	_	_	_	_	_
25	IBD	_	_	NNP	_	_	_	_	_
26	development	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	attenuate	_	_	VB	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	excessive	_	_	JJ	_	_	_	_	_
5	immune	_	_	JJ	_	_	_	_	_
6	response	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	advanced	_	_	JJ	_	_	_	_	_
9	immunotherapy	_	_	NN	_	_	_	_	_
10	using	_	_	VBG	_	_	_	_	_
11	immune-modulators	_	_	NNS	_	_	_	_	_
12	such	_	_	JJ	_	_	_	_	_
13	as	_	_	IN	_	_	_	_	_
14	inflammatory	_	_	JJ	_	_	_	_	_
15	cytokine	_	_	NN	_	_	_	_	_
16	blockers	_	_	NNS	_	_	_	_	_
17	has	_	_	VBZ	_	_	_	_	_
18	been	_	_	VBN	_	_	_	_	_
19	used	_	_	VBN	_	_	_	_	_
20	recently	_	_	RB	_	_	_	_	_
21	;	_	_	:	_	_	_	_	_
22	however	_	_	RB	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	presence	_	_	NN	_	_	_	_	_
26	of	_	_	IN	_	_	_	_	_
27	non-responder	_	_	JJ	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	uncontrolled	_	_	JJ	_	_	_	_	_
30	side	_	_	NN	_	_	_	_	_
31	effects	_	_	NNS	_	_	_	_	_
32	are	_	_	VBP	_	_	_	_	_
33	the	_	_	DT	_	_	_	_	_
34	common	_	_	JJ	_	_	_	_	_
35	challenging	_	_	JJ	_	_	_	_	_
36	issues	_	_	NNS	_	_	_	_	_
37	when	_	_	WRB	_	_	_	_	_
38	using	_	_	VBG	_	_	_	_	_
39	immunotherapy	_	_	NN	_	_	_	_	_
40	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	there	_	_	EX	_	_	_	_	_
4	has	_	_	VBZ	_	_	_	_	_
5	been	_	_	VBN	_	_	_	_	_
6	an	_	_	DT	_	_	_	_	_
7	unmet	_	_	JJ	_	_	_	_	_
8	need	_	_	NN	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	develop	_	_	VB	_	_	_	_	_
11	novel	_	_	JJ	_	_	_	_	_
12	therapeutics	_	_	NNS	_	_	_	_	_
13	for	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	effective	_	_	JJ	_	_	_	_	_
16	management	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	IBD	_	_	NNP	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	we	_	_	PRP	_	_	_	_	_
6	investigated	_	_	VBD	_	_	_	_	_
7	whether	_	_	IN	_	_	_	_	_
8	Ech	_	_	NNP	_	_	_	_	_
9	A	_	_	NNP	_	_	_	_	_
10	could	_	_	MD	_	_	_	_	_
11	exhibit	_	_	VB	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	protective	_	_	JJ	_	_	_	_	_
14	role	_	_	NN	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	IBD	_	_	NNP	_	_	_	_	_
17	progression	_	_	NN	_	_	_	_	_
18	using	_	_	VBG	_	_	_	_	_
19	a	_	_	DT	_	_	_	_	_
20	chemical	_	_	JJ	_	_	_	_	_
21	colitogen	_	_	NN	_	_	_	_	_
22	dextran	_	_	NN	_	_	_	_	_
23	sodium	_	_	NN	_	_	_	_	_
24	sulfate	_	_	NN	_	_	_	_	_
25	(	_	_	-LRB-	_	_	_	_	_
26	DSS)-induced	_	_	JJ	_	_	_	_	_
27	colitis	_	_	NN	_	_	_	_	_
28	mice	_	_	NNS	_	_	_	_	_
29	model	_	_	NN	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	explore	_	_	VB	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	therapeutic	_	_	JJ	_	_	_	_	_
5	mechanism	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	Ech	_	_	NNP	_	_	_	_	_
8	A	_	_	NNP	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	we	_	_	PRP	_	_	_	_	_
11	also	_	_	RB	_	_	_	_	_
12	performed	_	_	VBD	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	vitro	_	_	NN	_	_	_	_	_
15	proliferation	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	polarization	_	_	NN	_	_	_	_	_
18	experiments	_	_	NNS	_	_	_	_	_
19	with	_	_	IN	_	_	_	_	_
20	two	_	_	CD	_	_	_	_	_
21	major	_	_	JJ	_	_	_	_	_
22	innate	_	_	JJ	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	adaptive	_	_	JJ	_	_	_	_	_
25	immune	_	_	JJ	_	_	_	_	_
26	cells	_	_	NNS	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	macrophage	_	_	NN	_	_	_	_	_
29	and	_	_	CC	_	_	_	_	_
30	CD4+	_	_	NN	_	_	_	_	_
31	helper	_	_	NN	_	_	_	_	_
32	T	_	_	NN	_	_	_	_	_
33	cells	_	_	NNS	_	_	_	_	_
34	(	_	_	-LRB-	_	_	_	_	_
35	Th	_	_	NN	_	_	_	_	_
36	cells	_	_	NNS	_	_	_	_	_
37	)	_	_	-RRB-	_	_	_	_	_
38	,	_	_	,	_	_	_	_	_
39	respectively	_	_	RB	_	_	_	_	_
40	.	_	_	.	_	_	_	_	_


1	Our	_	_	PRP$	_	_	_	_	_
2	in	_	_	IN	_	_	_	_	_
3	vivo	_	_	NN	_	_	_	_	_
4	findings	_	_	NNS	_	_	_	_	_
5	suggest	_	_	VBP	_	_	_	_	_
6	that	_	_	IN	_	_	_	_	_
7	Ech	_	_	NNP	_	_	_	_	_
8	A	_	_	NNP	_	_	_	_	_
9	could	_	_	MD	_	_	_	_	_
10	attenuate	_	_	VB	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	clinical	_	_	JJ	_	_	_	_	_
13	signs	_	_	NNS	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	as	_	_	RB	_	_	_	_	_
16	well	_	_	RB	_	_	_	_	_
17	as	_	_	IN	_	_	_	_	_
18	histological	_	_	JJ	_	_	_	_	_
19	improvement	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	for	_	_	IN	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	first	_	_	JJ	_	_	_	_	_
24	time	_	_	NN	_	_	_	_	_
25	in	_	_	IN	_	_	_	_	_
26	a	_	_	DT	_	_	_	_	_
27	colitis	_	_	NN	_	_	_	_	_
28	model	_	_	NN	_	_	_	_	_
29	which	_	_	WDT	_	_	_	_	_
30	represents	_	_	VBZ	_	_	_	_	_
31	IBD	_	_	NNP	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	More	_	_	RBR	_	_	_	_	_
2	importantly	_	_	RB	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	vitro	_	_	NN	_	_	_	_	_
6	results	_	_	NNS	_	_	_	_	_
7	demonstrate	_	_	VBP	_	_	_	_	_
8	that	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	anti-inflammatory	_	_	JJ	_	_	_	_	_
11	function	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	Ech	_	_	NN	_	_	_	_	_
14	A	_	_	NN	_	_	_	_	_
15	is	_	_	VBZ	_	_	_	_	_
16	manifested	_	_	VBN	_	_	_	_	_
17	by	_	_	IN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	part	_	_	NN	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	inducing	_	_	VBG	_	_	_	_	_
23	immunomodulatory	_	_	JJ	_	_	_	_	_
24	effector	_	_	NN	_	_	_	_	_
25	cells	_	_	NNS	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	such	_	_	JJ	_	_	_	_	_
28	as	_	_	IN	_	_	_	_	_
29	M2	_	_	NN	_	_	_	_	_
30	macrophages	_	_	NNS	_	_	_	_	_
31	and	_	_	CC	_	_	_	_	_
32	Treg	_	_	NNP	_	_	_	_	_
33	cells	_	_	NNS	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_

